Related Experiment Video

Updated: Aug 24, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Use of antituberculosis drugs in Spain 1996

A Blázquez Pérez¹, R M Mateos Campos

¹Department of Preventive Medicine and Public Health, University of Salamanca, Campo Charro s/n 37007 Salamanca, Spain.

Pharmacoepidemiology and Drug Safety

|April 10, 2004

Abstract

Purpose:

To determine and analyse the consumption of antituberculosis agents in Spain.

Methods:

Pharmacoepidemiological study on the use of antituberculosis agents during 1996 using data from prescriptions redeemed by the National Health Service.

Results:

During 1996, 5 533 233 defined daily doses (DDD) were consumed. Of these, 2 215 890 DDDs belonged to a combination commercialized as Rifinah (Rifampicin+Isoniazid). The use of daily doses per inhabitant in Spain was 0.37. Regarding the percentage of use, this reflects a use of 40.05% of the Rifinah combination, followed by Rifampicin, 17.59%. Regarding estimation of tuberculosis, the findings of the study revealed 11,202 cases, implying a prevalence of 27.7 cases per 100,000 inhabitants. The total cost of this group of drugs was 863 275 147 Pts (0.1% of the total amount met by the NHS). Expenditure in Pts per 1000 inhabitants was 21 326. Of total costs, 40.26% was from Rifinah. Isoniazid was the drug with the lowest cost, 0.17%.

Conclusions:

The most prescribed drug in Spain was the Rifampicin+Isoniazid combination. However, differences exist in the different regions of the country and these should receive further study. The estimated prevalence of tuberculosis is higher than that expected for a developed country such as Spain.

More Related Videos

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells

Published on: May 22, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Articles linked to this work by shared authors, journal, and citation graph.

[The use of antitubercular drugs in primary care].

Atencion primaria·1999

See all related articles